(Q39586204)

13 September 2017

Low-dose docetaxel enhances the sensitivity of S-1 in a xenograft model of human castration resistant prostate cancer (English)

1 reference

13 September 2017

1 reference

1 reference

Masanori Hasegawa

1

1 reference

13 September 2017

Akira Miyajima

2

1 reference

13 September 2017

Takeo Kosaka

3

1 reference

13 September 2017

Yota Yasumizu

4

1 reference

13 September 2017

Nobuyuki Tanaka

5

1 reference

13 September 2017

Takahiro Maeda

6

1 reference

13 September 2017

Suguru Shirotake

7

1 reference

13 September 2017

Hiroki Ide

8

1 reference

13 September 2017

Eiji Kikuchi

9

1 reference

13 September 2017

Mototsugu Oya

10

1 reference

13 September 2017

language of work or name

English

0 references

publication date

25 April 2011

1 reference

International Journal of Cancer

13 September 2017

1 reference

13 September 2017

130

1 reference

13 September 2017

2

1 reference

13 September 2017

431-442

1 reference

13 September 2017

Cancer statistics, 2009

1 reference

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

21 January 2018

1 reference

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

21 January 2018

1 reference

Thymidylate synthase and drug resistance

21 January 2018

1 reference

Thymidylate synthase was associated with patient prognosis and the response to adjuvant therapy in bladder cancer

21 January 2018

1 reference

Overexpression of thymidylate synthase mediates desensitization for 5-fluorouracil of tumor cells

21 January 2018

1 reference

Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine

21 January 2018

1 reference

S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial

21 January 2018

1 reference

Phase II study of oral S-1 for treatment of metastatic colorectal carcinoma

21 January 2018

1 reference

Randomized scheduling feasibility study of S-1 for adjuvant chemotherapy in advanced head and neck cancer

21 January 2018

1 reference

A phase II study of S-1 in patients with metastatic breast cancer--a Japanese trial by the S-1 Cooperative Study Group, Breast Cancer Working Group

21 January 2018

1 reference

Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer

21 January 2018

1 reference

Phase II study of S-1 in patients with advanced biliary tract cancer

21 January 2018

1 reference

Derivation of androgen-independent human LNCaP prostatic cancer cell sublines: role of bone stromal cells

21 January 2018

1 reference

Angiotensin II type 1 receptor antagonist candesartan as an angiogenic inhibitor in a xenograft model of bladder cancer.

21 January 2018

1 reference

Angiotensin II type 1 receptor antagonist as an angiogenic inhibitor in prostate cancer

21 January 2018

1 reference

Angiotensin II type 1 receptor antagonist enhances cis-dichlorodiammineplatinum-induced cytotoxicity in mouse xenograft model of bladder cancer.

21 January 2018

1 reference

Pharmacokinetic advantage of intraperitoneal injection of docetaxel in the treatment for peritoneal dissemination of cancer in mice.

21 January 2018

1 reference

Vitamin E succinate induced apoptosis and enhanced chemosensitivity to paclitaxel in human bladder cancer cells in vitro and in vivo.

21 January 2018

1 reference

Evaluation of combination chemotherapy: integration of nonlinear regression, curve shift, isobologram, and combination index analyses

21 January 2018

1 reference

Prolonged and enhanced suppression of thymidylate synthase by weekly 24-h infusion of high-dose 5-fluorouracil

21 January 2018

1 reference

Expression of thymidylate synthase in human cells is an early G(1) event regulated by CDK4 and p16INK4A but not E2F.

21 January 2018

1 reference

Evidence that low doses of Taxol enhance the functional transactivatory properties of p53 on p21 waf promoter in MCF-7 breast cancer cells

21 January 2018

1 reference

Weekly paclitaxel and high-dose 5-fluorouracil plus leucovorin in hormone-refractory prostate cancer: in vitro combined effects and a phase II trial

21 January 2018

1 reference

Capecitabine in hormone-resistant metastatic prostatic carcinoma - a phase II trial

21 January 2018

1 reference

Phase II trial of capecitabine and weekly docetaxel for metastatic castrate resistant prostate cancer

21 January 2018

1 reference

Efficacy of S-1 in patients with castration-resistant prostate cancer: a phase II study

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/IJC.26012

1 reference

release_ug5dtng3dvew5odmjjf4w3rjem

13 September 2017

0 references

1 reference